IBDEI1JB ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,24839,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24839,1,3,0)
 ;;=3^Resp Failure,Chronic,Unspec w/ Hypoxia or Hypercapnia
 ;;^UTILITY(U,$J,358.3,24839,1,4,0)
 ;;=4^J96.10
 ;;^UTILITY(U,$J,358.3,24839,2)
 ;;=^5008350
 ;;^UTILITY(U,$J,358.3,24840,0)
 ;;=J96.12^^85^1092^10
 ;;^UTILITY(U,$J,358.3,24840,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24840,1,3,0)
 ;;=3^Resp Failure,Chronic w/ Hypercapnia
 ;;^UTILITY(U,$J,358.3,24840,1,4,0)
 ;;=4^J96.12
 ;;^UTILITY(U,$J,358.3,24840,2)
 ;;=^5008352
 ;;^UTILITY(U,$J,358.3,24841,0)
 ;;=J96.11^^85^1092^11
 ;;^UTILITY(U,$J,358.3,24841,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24841,1,3,0)
 ;;=3^Resp Failure,Chronic w/ Hypoxia
 ;;^UTILITY(U,$J,358.3,24841,1,4,0)
 ;;=4^J96.11
 ;;^UTILITY(U,$J,358.3,24841,2)
 ;;=^5008351
 ;;^UTILITY(U,$J,358.3,24842,0)
 ;;=R06.03^^85^1092^4
 ;;^UTILITY(U,$J,358.3,24842,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24842,1,3,0)
 ;;=3^Resp Distress,Acute
 ;;^UTILITY(U,$J,358.3,24842,1,4,0)
 ;;=4^R06.03
 ;;^UTILITY(U,$J,358.3,24842,2)
 ;;=^5151591
 ;;^UTILITY(U,$J,358.3,24843,0)
 ;;=J80.^^85^1092^3
 ;;^UTILITY(U,$J,358.3,24843,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24843,1,3,0)
 ;;=3^Resp Distress Syndrome,Acute (ARDS)
 ;;^UTILITY(U,$J,358.3,24843,1,4,0)
 ;;=4^J80.
 ;;^UTILITY(U,$J,358.3,24843,2)
 ;;=^5008294
 ;;^UTILITY(U,$J,358.3,24844,0)
 ;;=S23.9XXA^^85^1093^20
 ;;^UTILITY(U,$J,358.3,24844,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24844,1,3,0)
 ;;=3^Sprain Thorax,Unspec Part,Initial Encounter
 ;;^UTILITY(U,$J,358.3,24844,1,4,0)
 ;;=4^S23.9XXA
 ;;^UTILITY(U,$J,358.3,24844,2)
 ;;=^5023267
 ;;^UTILITY(U,$J,358.3,24845,0)
 ;;=I69.928^^85^1093^14
 ;;^UTILITY(U,$J,358.3,24845,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24845,1,3,0)
 ;;=3^Speech/Lang Deficits Following Unspec Cerebrovascular Disease
 ;;^UTILITY(U,$J,358.3,24845,1,4,0)
 ;;=4^I69.928
 ;;^UTILITY(U,$J,358.3,24845,2)
 ;;=^5007557
 ;;^UTILITY(U,$J,358.3,24846,0)
 ;;=S13.4XXA^^85^1093^19
 ;;^UTILITY(U,$J,358.3,24846,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24846,1,3,0)
 ;;=3^Sprain Ligaments Cervical Spine,Initial Encounter
 ;;^UTILITY(U,$J,358.3,24846,1,4,0)
 ;;=4^S13.4XXA
 ;;^UTILITY(U,$J,358.3,24846,2)
 ;;=^5022028
 ;;^UTILITY(U,$J,358.3,24847,0)
 ;;=M15.3^^85^1093^5
 ;;^UTILITY(U,$J,358.3,24847,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24847,1,3,0)
 ;;=3^Secondary Multiple Arthritis
 ;;^UTILITY(U,$J,358.3,24847,1,4,0)
 ;;=4^M15.3
 ;;^UTILITY(U,$J,358.3,24847,2)
 ;;=^5010765
 ;;^UTILITY(U,$J,358.3,24848,0)
 ;;=L08.9^^85^1093^10
 ;;^UTILITY(U,$J,358.3,24848,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24848,1,3,0)
 ;;=3^Skin Infection,Unspec
 ;;^UTILITY(U,$J,358.3,24848,1,4,0)
 ;;=4^L08.9
 ;;^UTILITY(U,$J,358.3,24848,2)
 ;;=^5009082
 ;;^UTILITY(U,$J,358.3,24849,0)
 ;;=L98.9^^85^1093^11
 ;;^UTILITY(U,$J,358.3,24849,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24849,1,3,0)
 ;;=3^Skin/Subcutaneous Tissue Disorder,Unspec
 ;;^UTILITY(U,$J,358.3,24849,1,4,0)
 ;;=4^L98.9
 ;;^UTILITY(U,$J,358.3,24849,2)
 ;;=^5009595
 ;;^UTILITY(U,$J,358.3,24850,0)
 ;;=R22.2^^85^1093^21
 ;;^UTILITY(U,$J,358.3,24850,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24850,1,3,0)
 ;;=3^Swelling,Mass & Lump,Trunk
 ;;^UTILITY(U,$J,358.3,24850,1,4,0)
 ;;=4^R22.2
 ;;^UTILITY(U,$J,358.3,24850,2)
 ;;=^5019286
 ;;^UTILITY(U,$J,358.3,24851,0)
 ;;=M54.31^^85^1093^3
 ;;^UTILITY(U,$J,358.3,24851,1,0)
 ;;=^358.31IA^4^2
